Beigene, LTD Form 4 insider transactions

Wang Xiaodong, a director at BeiGene, Ltd., reported the sale of American Depositary Shares (ADS) on February 4, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Director Wang Xiaodong of BeiGene, Ltd. sold a portion of his American Depositary Shares (ADS) under a pre-arranged 10b5-1 trading plan.

BeiGene's CEO, John Oyler, exercised options to acquire 1.3 million ordinary shares at $0.50 per share, while also holding significant indirect ownership through various trusts and entities.

A BeiGene director, Wang Xiaodong, sold a significant number of American Depositary Shares (ADS) and exercised share options under a pre-arranged trading plan.

Baker Bros. Advisors LP and related entities have reported the sale of a substantial number of BeiGene American Depositary Shares (ADS) and ordinary shares, while also disclosing their indirect beneficial ownership.

A BeiGene executive disposed of a portion of their economic interest in RMB Shares, receiving approximately $120,894 in net proceeds.

HHLR Advisors and Hillhouse Investment Management jointly report the sale of 17,842,500 BeiGene ordinary shares, equivalent to 1,372,500 ADSs, at a price of $200 per ADS.

Director Wang Xiaodong of BeiGene, Ltd. executed multiple sales of American Depositary Shares (ADS) on November 26, 2024, under a pre-arranged 10b5-1 trading plan.

BeiGene's CEO, John Oyler, executed multiple sales of American Depositary Shares (ADS) on October 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Shalini Sharp reports acquisition of 8,151 ordinary shares and 17,238 share options in BeiGene, Ltd.

Chan Henry Lee, SVP and General Counsel of BeiGene, Ltd., sold 1,202 American Depositary Shares on September 30, 2024, at a price of $237.10 per share, according to a Form 4 filing with the SEC.

Lai Wang, Global Head of R&D at BeiGene, Ltd., reports the sale of 5,000 American Depositary Shares (ADS) at a price of $220.3548 per share on September 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

BeiGene's President, COO & GM China, Wu Xiaobin, reports sales of American Depositary Shares (ADS) under a pre-arranged Rule 10b5-1 trading plan.

Xiaobin Wu, President, COO & GM China of BeiGene, Ltd., sold American Depositary Shares (ADS) on September 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Titus B. Ball, Principal Accounting Officer of BeiGene, Ltd., sold American Depositary Shares to satisfy tax withholding obligations related to vesting restricted share units.

Director Wang Xiaodong reports a gift of 301,457 ordinary shares of BeiGene, Ltd.

Chief Financial Officer of BeiGene, Aaron Rosenberg, reports acquisition of ordinary shares and share options.

Chan Henry Lee, SVP and General Counsel of BeiGene, Ltd., sold 834 American Depositary Shares on July 30, 2024, to satisfy tax withholding obligations related to vesting restricted share units.

Chief Financial Officer Julia Wang sold American Depositary Shares of BeiGene, Ltd. to satisfy tax withholding obligations related to vesting restricted share units.

Julia Wang, CFO of BeiGene, Ltd., sold 899 American Depositary Shares on June 24, 2024, to satisfy tax withholding obligations related to vesting restricted share units.

Lai Wang, Global Head of R&D at BeiGene, Ltd., reports the sale of American Depositary Shares (ADS) to cover mandatory tax withholding obligations related to vesting restricted share units.

BeiGene's President, COO & GM China, Wu Xiaobin, sold American Depositary Shares (ADS) on June 24, 2024, to satisfy tax withholding requirements related to vesting restricted share units.

BeiGene's CEO, John Oyler, sold a portion of his American Depositary Shares (ADS) to satisfy tax obligations related to vesting restricted share units.

BeiGene's CEO, John Oyler, sold American Depositary Shares (ADS) on June 17, 2024, to satisfy tax obligations related to the vesting of restricted share units.

Julia Wang, CFO of BeiGene, Ltd., sold American Depositary Shares (ADS) on June 17, 2024, to satisfy tax withholding requirements related to vesting restricted share units.

Lai Wang, Global Head of R&D at BeiGene, Ltd., sold shares to cover tax obligations related to vesting restricted share units.

BeiGene's President, COO & GM China, Wu Xiaobin, sold American Depositary Shares (ADS) to cover tax obligations related to vesting restricted share units.

Chan Henry Lee, SVP, General Counsel of BeiGene, Ltd., sold American Depositary Shares (ADS) on June 17, 2024, to satisfy tax withholding obligations related to vesting restricted share units.

Titus B. Ball, Principal Accounting Officer of BeiGene, Ltd., reports acquiring and disposing of ordinary shares and acquiring share options.

BeiGene's President, COO & GM China, Wu Xiaobin, reports acquisition of ordinary shares and share options, as well as disposal of American Depositary Shares, according to a recent SEC Form 4 filing.